10-Q: Entera Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Entera Bio reported a net loss of $4.162 million for the first six months of 2024, while highlighting progress in its oral peptide programs and collaborations.

Summary

• Entera Bio, a clinical-stage company, released its financial results for the second quarter of 2024, showing a net loss of $4.162 million for the first six months of the year.
• The company's operating loss for the first six months was $4.227 million, compared to $4.542 million for the same period in 2023.
• Revenues for the three and six months ended June 30, 2024 were $57 thousand, attributed to a research services agreement.
• Research and development expenses decreased to $1.821 million for the first six months of 2024, down from $2.140 million in the same period of 2023.
• General and administrative expenses remained relatively stable at $2.415 million for the first six months of 2024, compared to $2.429 million in 2023.
• As of June 30, 2024, Entera Bio had cash and cash equivalents of $9.1 million.
• The company believes its current cash resources will fund operations into the third quarter of 2025, but additional funding will be needed for the Phase 3 study of EB613.
• Entera Bio is developing oral tablet formats of peptide and protein replacement therapies, with a focus on osteoporosis and hypoparathyroidism.
• The company is preparing to initiate a Phase 3 registrational study for EB613 for osteoporosis, pending FDA qualification of a BMD endpoint.
• Entera Bio is also collaborating with OPKO Biologics on oral GLP-2 and GLP-1/Glucagon programs.

Sentiment

Score: 4

Explanation: The document highlights some positive developments in the company's pipeline and collaborations, but the significant net loss, accumulated deficit, and going concern uncertainty weigh heavily on the overall sentiment. The need for additional funding is a major concern.

Positives

• Operating losses decreased to $4.227 million for the first six months of 2024, compared to $4.542 million in the same period of 2023.
• The company successfully generated $57 thousand in revenue from a research services agreement.
• Research and development expenses decreased to $1.821 million for the first six months of 2024, indicating potential cost efficiencies.
• Entera Bio has sufficient cash to fund operations into the third quarter of 2025.
• The company is progressing towards a Phase 3 study for EB613 for osteoporosis.
• Positive in vivo pharmacokinetic results were achieved in the collaboration with OPKO Biologics for the oral GLP-2 program.

Negatives

• The company reported a net loss of $4.162 million for the first six months of 2024.
• The company has an accumulated deficit of $108.5 million as of June 30, 2024.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company's ability to commence the Phase 3 study of EB613 depends on additional funding, which may not be available.
• The company has not generated significant revenue from product sales to date.

Risks

• The company's ability to continue as a going concern is uncertain without additional funding.
• The Phase 3 study for EB613 is dependent on securing additional capital.
• Clinical development involves a lengthy and expensive process with uncertain outcomes.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable.
• The company is subject to the risks of the ongoing Israel-Hamas war and the conflict with Iran and its proxies.
• The company relies on third parties for clinical trials and supply of product candidates.
• The company may not be able to obtain or maintain patent protection for its product candidates.
• The company has a limited operating history and a history of operating losses.

Future Outlook

The company believes its current cash resources will be sufficient to meet its projected operating requirements into the third quarter of 2025, but additional funding will be needed for the Phase 3 study of EB613. The company expects additional in vivo PK/PD data from both the oral GLP-2 tablet program and the oral OXM tablet program in 2024.

Management Comments

• Management is of the opinion that its available funds as of June 30, 2024 will allow the Company to operate under its current plans into the third quarter of 2025.
• Management continually evaluates various financing alternatives in the public and private equity markets, debt financing and strategic collaborations.
• Management is of the opinion that there is substantial doubt as to the Company's ability to continue as a going concern.

Industry Context

Entera Bio is operating in the competitive biopharmaceutical industry, focusing on oral delivery of peptide and protein therapies, which is a challenging area. The company's focus on osteoporosis and hypoparathyroidism addresses significant unmet medical needs. The collaboration with OPKO Biologics on GLP-2 and GLP-1/Glucagon programs aligns with the growing interest in these therapeutic areas.

Comparison to Industry Standards

• Entera Bio's focus on oral peptide delivery is a differentiating factor compared to many companies that rely on injectable biologics, such as Amgen (Prolia) and Eli Lilly (Forteo) in the osteoporosis space.
• The company's progress with EB613, aiming for a Phase 3 study, is a significant step, but it is still behind companies with approved therapies.
• The collaboration with OPKO Biologics on GLP-2 and GLP-1/Glucagon programs puts Entera in competition with companies like Novo Nordisk and Eli Lilly, which have established positions in the GLP-1 market.
• The company's financial position, with a significant accumulated deficit and reliance on future funding, is a common challenge for clinical-stage biotechs, similar to companies like Radius Health and Ascendis Pharma.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional funding.
• Employees may be affected by the company's financial instability and potential restructuring.
• Patients may benefit from the development of new oral therapies for osteoporosis and hypoparathyroidism, but the timeline for approval is uncertain.
• The company's suppliers and partners may be impacted by the company's financial situation and potential delays in development programs.

Next Steps

• The company is preparing to initiate a Phase 3 registrational study for EB613 for osteoporosis.
• The company will continue to advance its EB612 program for hypoparathyroidism.
• The company expects additional in vivo PK/PD data from both the oral GLP-2 tablet program and the oral OXM tablet program in 2024.
• The company will continue to evaluate various financing alternatives.

Key Dates

Keywords

Entera Bio, oral peptide, osteoporosis, hypoparathyroidism, EB613, EB612, GLP-2, OPKO Biologics, clinical trials, N-Tab technology, biopharmaceutical, bone mineral density, pharmaceutical, drug development